News

06/04/2018

New scientific publication of BioVentures Institute Ltd. in a high rank journal. The paper describes monographic work on TP-84 bacteriophage genomics, bioinformatics and proteomics analysis leading to the construction of a new thermostable, nanobiocarrier for bioactive molecules. It has been published in PLOS ONE: Skowron PM et. al.:: “Sequence, genome organization, annotation and proteomics of the thermophilic, 47.7-kb Geobacillus stearothermophilus bacteriophage TP-84 and its classification in the new Tp84virus genus.” PLOS ONE 2018, 13: e0195449

08/03/2018

The Republic of Poland Patent Office has granted a patent protecting BioVentures Institute Ltd. technology of the construction of artificial, concatameric proteins for multiple usage purposes, including new generation vaccines, entitled: “A method of obtaining a polyepitopic protein and a DNA vector for embodying this method.” (Pl title: “Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu”. The technology is also protected by EU, USA, Israel, Japan, China, India patent applications.

PATENT NR 228341

07/2017

BioVentures Institute Ltd. continues a long term cooperation with University of Gdansk and New England Biolabs Ltd. (USA), a world leader in the development and sales of enzymatic tools for recombinant DNA technologies. Our common project in the field of restriction endonucleases has resulted in solving a longstanding riddle of two RM.TaqII specificities, discovering a third RM system (RM.TaqIII) from T. aquaticus YT-1.  Results  were published in a high Impact Factor (10.2) journal – Nucleic Acid Research 2017, DOI: 10.1093/nar/gkx599. Among the authors is a Nobel Prize Nominee – prof. Richard Roberts.

01/2017

The new grant STRATEGMED TARGETTELO in the amount of 19 654 385.00 PLN issued by the National Center for Research and Development has been started by the academic-industrial consortium, composed of University of Gdańsk, Gdansk University of Technology, Medical University of Gdańsk, Institute of Immunology and Experimental Therapy Polish Academy of Sciences, Nencki Institute of Experimental Biology Polish Academy of Sciences, The Provincial Hospitals in Gdynia Ltd., EU-CONSULT Ltd. and  Innovabion Ltd.
BioVentures Institute Ltd. scientists continuing their close cooperation with the University of Gdansk will develop key components of the proposed technology aiming at design and construction of a  new anticancer compounds.

11/2016

BioVentures Ltd. has extended the international PCT patent application no WO 2015162560 A1, covering the technology of construction of artificial, poly-epitopic proteins to the following countries: USA, EU, Israel, Japan, China, India.

11/2016

BioVentures Institute Ltd.  International PCT patent application, entitled “A method of obtaining a polyepitopic protein as well as a DNA vector for embodying this method.” has been assigned no 2015162560 A1 (2015). The patent application protects BioVentures Institute Ltd. technology of the construction of artificial, concatameric proteins for multiple usage purposes, including new generation vaccines. The application has been extended to EU, USA, Japan, China, Isreal, India.

PCT patent application no 2015162560 A1

15/09/2016

BioVentures Institute Ltd. filed a Republic of Poland patent application. The patent application no P.418712: „A method of usage of the nucleotide sequence and coding Open Reading Frames of the thermophilic bacteriophage TP-84 genome, which infect Bacillus (Geobacillus) species” describes the use in biotechnology of the thermophilic bacteriophage TP-84-coded proteins.

18/08/2016

Merging  BioVentures Institute Ltd. with Polivac Ltd. has been completed.

National Court Register

06/05/2016

Merging  BioVentures Institute Ltd. with Polivac Ltd. 

Projekt uchwały NZW Polivac Sp. o.o. o połączeniu spółek Projekt uchwały Zarządu BioVentures Institute Sp. zo.o. o połączeniu spółek 

2/2016

The cooperation in the area of engineering of enzymes performance for biotechnology purposes between BioVentures Institute Ltd. and  Dept. of Molecular Biotechnology, Institute for Environmental and Human Health Protection, Faculty of Chemistry, University of Gdansk, has resulted in generation of  new “molecular scissors” for DNA cleavage. Results have been published in high level international scientific journal "Engineering TaqII bifunctional endonuclease DNA recognition fidelity: the effect of a single amino acid substitution within the methyltransferase catalytic site" Molecular Biology Reports 2016, DOI 10.1007/s11033-016-3949-3

10/2015

Barentzymes AS, a Norwegian biotechnology company (part of Fluenta holding) has signed long term cooperation agreement with BioVentures Institute Ltd. concerning development of enzymatic tools for waste utilisation and environment pollution control.

19/06/2015

Professor Piotr Skowron received the 1st award granted by the Pomeranian Employers Association in the category “Primum Cooperatio” i.e. “first and foremost cooperation” during the 2015 Business Gala held in the Grand Hotel in Sopot (Poland). According to the Jury, Professor Piotr Skowron proved that his cooperation between the scientific and economic environment, which has lasted more than 20 years now, brings tangible benefits to business and science.


From the left – professor Bernard Lammek, presenter who announced the laureate’s achievements, Gdansk University Chairman, middle – professor Piotr Skowron, right – professor Edmund Wittbrodt – senator of the Republic of Poland. 

Photo 01 Photo 02
Info 01 Info 02 Info 03

21/04/2015

BioVentures Institute Ltd. filed an international patent application (PCT). Title of the application: „A method of obtaining a polyepitopic protein as well as a DNA vector for embodying this method”, describing a novel technology for the construction of artificial polyepitopic proteins, applied to construction of recombinant vaccines, among other applications. The application has received positive verification from the PCT International Search Report.

WO 2015/162560 A1

Validation of an epitope amplification – 500-mer

 

03/2015

In cooperation with the University of Gdańsk, BioVentures Institute Ltd. has established funds and applied research programmes for biotechnology, chemistry and biology undergraduate students' laboratory practices, graduate students' complete research for Master’s and Ph.D. degrees, as well as for performing advanced molecular biotechnology projects for D.Sc. (habilitation) candidates.

07/01/2015

BioVentures Institute Ltd. received the highest ‘A’ score for technological novelty presented in the Republic of Poland patent application, entitled „A method of obtaining a polyepitopic protein as well as a DNA vector for embodying this method” from Department of Patent Search, Patent Office of the Republic of Poland. The patent application describes a novel technology for the construction of recombinant vaccines.

10/2014

Scientists from the BioVentures Institute Ltd. continue their cooperation with the University of Gdansk in the area of regenerative medicine, employing advanced recombinant DNA technologies. The new grant STRATEGMED in the amount of 17 767 556.00 PLN issued by the National Center for Research and Development has been started by the academic-industrial consortium REGENNOVA.

More info.

07/2014

Piotr Skowron  has received professor title in biological sciences. On 28 July, accordingly to positive reviews and decision of Central Commission for Academic Degrees and Titles, President of The Republic of Poland awarded professor title to Piotr Skowron, President of BioVentures Institute Ltd.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

President Bronisław Komorowski and Piotr Skowron durring aword ceremony.

Photo: Wojciech Olkusnik, source: The Chancellery of the President of the Republic of Poland

 

4/2014

Scientific research advances achieved in BioVentures Institute Ltd. supported by National Centre for Research and Development (NCBiR), SATUS VC and Jagiellonian Centre of Innovation Ltd. have led to filing a patent application no P.407950, protecting the developed recombinant vaccine biotechnology. The applied gene cloning and protein engineering methodology enables construction of artificial antigens, with a highly increased immune system stimulation potential.

23/04/2014

BioVentures Institute Ltd. filed a Republic of Poland patent application, entitled “Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu.” (Eng.: A method of obtaining a polyepitopic protein as well as a DNA vector for embodying this method.) The patent application describes a novel technology for the construction of artificial polyepitopic proteins, applied to construction of recombinant vaccines, among other applications.

P 407 950

2/2014

BioVentures Institute Ltd. has established  three funds for advanced molecular biotechnology Ph.D. students from The Dept. of Chemistry, University of Gdansk and Dept. of Chemistry, Technical University of Gdansk.

1/2014

The cooperation in the area of gene cloning and engineering of enzymes for biotechnology applications between BioVentures Institute Ltd. and  Dept. of Molecular Biotechnology, Institute for Environmental and Human Health Protection, Faculty of Chemistry, University of Gdansk, has resulted in generation of  new “molecular scissors” for DNA cleavage. Results have been published in two high level international scientific journals (“Modified 'one amino acid-one codon' engineering of high GC content TaqII-coding gene from thermophilic Thermus aquaticus results in radical expression increase.”  Microbial Cell Factories  2014, 13:7. and “Cofactor analogue-induced chemical reactivation of endonuclease activity in a DNA cleavage/methylation deficient TspGWI N473A variant in the NPPY motif.” Molecular Biology Reports  2014, DOI:10.1007/s11033-014-3085-x.)

12/2013

BioVentures Institute Ltd. has accepted a venture capital entry by SATUS Venture Capital and Jagiellonian Centre of Innovation Ltd. JCI Ltd. is a business broker in bio partnering and collaboration in Poland. JCI manages the first dedicated Life Science Park in Central and Eastern Europe.  The JCI administers also the Life Science Cluster Krakow & Polish Biotechnology Platform. They are an associations of member companies and organizations (including Jagiellonian University, Krakow, Poland), which represents the biggest commercial potential for the biosciences in Poland. SATUS VC is a group of commercial entities managing seed and vc capitals, focusing on highly innovative technological companies, with a potentially highest investment return, mainly in the area of ITC, biotechnology and engineering.

8/2013

The continued scientific cooperation between BioVentures Institute Ltd., Thermo Fisher Scientific and Department of Molecular Biotechnology, Institute for Environmental and Human Health Protection, Faculty of Chemistry, University of Gdansk, has brought further discoveries in the area of generation of new molecular tools for genetic engineering. Results have been published in an recognized scientific journal (“Three-stage biochemical selection: cloning of prototype class IIS/IIC/IIG restriction endonuclease-methyltransferase TsoI from the thermophile Thermus scotoductus.” BMC Molecular Biology, 2014, 14:17.).

6/2013

INVESTIN programme in cooperation with BioVentures Institute Ltd. has established two funds for advanced molecular biotechnology D.Sc. (habilitation) candidates from The Dept. of Chemistry, University of Gdansk.

10/2012

BioVentures Institute Ltd. received funding from the European Union (EU) via National Centre for Research and Development (NCBiR) in the amount of 3 209 930 PLN (POIG.01.04.00-22-140/12) for the development of novel, recombinant DNA based technology in cooperation with the Molecular Biotechnology Department, Chemistry Division and Molecular Biology Department, Biology Division, University of Gdansk, of generating artificial hyper immunogenic antigens/vaccines, entitled: „The new technology of producing preventive and therapeutic vaccines for multiple stimulation of the human immune system”. The technology is universal, thus can be applied to most antigens, however, our first targets are HIV, HCV and HBV viruses.

8/2012

Our biotechnology projects partner MedVentures Ltd. (Poznan, Poland) has received financing from a strategic investor Nickel Technology Park Poznan. MedVentures that specializes in the development of innovative therapies for accelerated wound healing. With the support of Nickel Incubator which amounts to 200 000 EUR the company will run their researches in cooperation with the Chemistry Division, University of Gdansk, and prepare a prototype of an innovative bioactive hydrogel dressing. In addition to features such as: reduction of exudate, physical protection or the protection against bacterial, viral and fungal infections, the new dressing will have a number of additional advantages. With specially formulated active substances concentrated in the hydrogel the process of healing will result in much faster and more effective treatment of chronic wounds with a complex ethiology as well as typical traumatic wounds. The dressing can be in any size, and the application and removal should be easy and painless. Moreover, it is 100% biodegradable and employs no chemical polymerization process. Ready-to-sell product is anticipated to reach the market in about 1.5 years.

4/2012

The scientific cooperation between BioVentures Institute Ltd., Thermo Fisher Scientific and Department of Environmental Molecular Biotechnology, Institute for Environmental and Human Health Protection, Faculty of Chemistry, University of Gdansk, has brought discoveries in the area of generation of new molecular tools for genetic engineering. Selected results have been published in an influential scientific journal (“Related bifunctional restriction endonuclease-methyltransferase triplets: TspDTI, Tth111II/TthHB27I and TsoI with distinct specificities.” BMC Molecular Biology, 2012, 13:13).

3/2012

Research affiliation between BioVentures Institute Ltd. and Department of Hepatology and Acquired Immunodeficiency, Medical University of Warsaw (Poland) concerning novel recombinant antiviral vaccines generation strategy has been established. The cooperation has already resulted in shared grant applications and obtaining positive experimental results in the construction of specialized DNA vectors and fusion proteins designed for use in the area of applied medicine.

11/2011

Long term research cooperation agreement in the field of molecular biotechnology has been signed between BioVentures Institute Ltd. and Thermo Fisher Scientific (USA; Fermentas branch, Lithuania). Thermo Fisher Scientific is a worldwide leading chemical company with revenues of $12 billion and 39,000 employees.

_

_

_

_

Hello world. This my website!

Hello world. This my website!

Hello world. This my website!

Hello world. This my website!

Hello world. This my website!

Hello world. This my website!

 

Partners

 

A PROJECT CO-FINANCED BY THE EUROPEAN UNION FROM THE EUROPEAN REGIONAL DEVELOPMENT FUND GRANTS FOR INNOVATION